Oncology

Biomedical Research in Urology

Joan Morote

Researchers
Rosanna Paciucci Barzanti, Mireia Olivan Riera, Carlos Fernández Sáez, Inés de Torres, Jacques Planas, Carles Raventós, Anna Celma, José Placer, Marta Allué, Carlos Salvador, Jorge Ropero, Fernando Lozano, Juan María Bastarós

Researchers in training
Verónica Cánovas Hernández, Iolanda Garcia Grau

Technician and administrative staff
Yolanda Puñal Ostosand Elisabet Olivan Riera

 

SUMMARY

We discovered the oncogenic actions of the Prostate Tumor OVerexpressed-1 (PTOV1) gene in the promotion of cell proliferation and metastatic dissemination of prostate cancer cells (1,2). Mechanistically, we showed that PTOV1 is implicated in multiple processes controlling cell fate such as (i) induction of mRNA translation that leads to a specific increased translation of c-Jun and Snai1 oncogenes (1), and (ii) PTOV1 is a transcriptional repressor of HES1 and HEY1 genes, leading to inhibition of Notch signaling in metastatic prostate cancer (2). PTOV1 significantly affect the self-renewal potential of the cancer stem cell populations of PC3 cells (2).   

Furthermore, anti-cancer properties of a Cyclooxygenase-2 inhibitor (celecoxib) were studied. Our results demonstrated that, in a preclinical mice model, celecoxib administered orally at the standard human dose inhibits the progression of established prostate cancer bone metastases (3). Other studies demonstrated the important role of serum cholesterol and statin use in the risk of prostate cancer detection and tumor aggressiveness (4).

PUBLICATIONS

Total 24.
Impact Factor 85.425
Average I.F. 3.56

  • Marqués N, Sesé M, Cánovas V, Valente F, Bermudo R, de Torres I, Fernández Y, Abasolo I, Fernández PL, Contreras H, Castellón E, Celià-Terrassa T, Méndez R,Ramón Y Cajal S, Thomson TM, Paciucci R. Regulation of protein translation and c-Jun expression by prostate tumor overexpressed 1. Oncogene. 2014;33(9):1124-34. doi: 10.1038/onc.2013.51. PMID:23455324. Impact source: ISI Category: GENETICS & HEREDITY Impact index in year of publication: 7.357.
  • Alaña L, Sesé M, Cánovas V, Punyal Y, Fernández Y, Abasolo I, de Torres I,Ruiz C, Espinosa L, Bigas A, Y Cajal SR, Fernández PL, Serras F, Corominas M, Thomson TM, Paciucci R. Prostate tumor OVerexpressed-1 (PTOV1) down-regulates HES1 and HEY1 notch targets genes and promotes prostate cancer progression. Mol Cancer. 2014;13:74. doi: 10.1186/1476-4598-13-74. PubMed PMID: 24684754; Impact source: ISI Category: BIOCHEMISTRY & MOLECULAR BIOLOGY Impact index in year of publication: 5.134.
  • Garcia M, Velez R, Romagosa C, Majem B, Pedrola N, Olivan M, Rigau M, Guiu M, Gomis RR, Morote J, Reventós J, Doll A. Cyclooxygenase-2 inhibitor suppresses tumour progression of prostate cancer bone metastases in nude mice. BJU Int. 2014;113(5b) E164-77.
 IF: 3.046
  • Morote J, Celma A, Planas J, Placer J, de Torres I, Olivan M, Carles J, Reventós J, Doll A. Role of serum cholesterol and statin use in the risk of prostate cancer detection and tumor aggressiveness. Int J Mol Sci. 2014;15(8),13615-23 IF: 2.339
  • Morote J, Gómez-Caamaño A, Alvarez-Ossorio JL, Pesqueira D, Tabernero A, Gómez Veiga F, Lorente JA, Porras M, Lobato JJ, Ribal MJ, Planas J; ANAMET Investigators Group. The Metabolic Syndrome and its Components in Patients with Prostate Cancer on Androgen Deprivation Therapy. J Urol. 2014. pii: S0022-5347(14)05140-4. doi: 10.1016/j.juro.2014.12.086. PubMed PMID: 25541340. IF: 3.573.

View all the publications

MAIN RESEARCH PROJECTS

  • Translational reprogramming and mitotic control in advanced resistant cancer.
    Entity where project took place: FUNDACIO INSTITUT DE RECERCA DE L’HOSPITAL UNIV. VALL D’HEBRON
    Name principal investigator (PI, Co-PI….): Rosanna Paciucci
    Nº of researchers: 5
    Funding entity or bodies: AGAUR, Government of Catalunya
    Start-End date: 2014 – 2017
  • Translational Oncology of hormone-dependient tumors. RD12/0036/0035
    Entity where project took place: FUNDACIO INSTITUT DE RECERCA DE L’HOSPITAL UNIV. VALL D’HEBRON
    Name principal investigator (PI, Co-PI….): Jaume Reventós Puijaner
    Start-End date: 2013 – 2016
    Total amount: 227.700
  • The protein PTOV1 regulates protein translation and Notch signaling. Relevance in cancer. SAF 2011-30496
    Degree of contribution: Coordinator of total project, network or consortium
    Entity where project took place: FUNDACIO INSTITUT DE RECERCA DE L’HOSPITAL UNIV. VALL D’HEBRON
    Name principal investigator (PI, Co-PI….): Rosanna Paciucci
    Nº of researchers: 4 Nª people/year: 4
    Funding entity or bodies: Ministerio de Ciencia e Innovación. Investigación Type of entity: publico. City funding entity: Madrid, Community of Madrid, Spain
    Name of the programme: Biomedicina
    Code according to the funding entity: SAF 2011-30496
    Start-End date: 01/2012 – 12/2014 Duration: 3 years
    Total amount: 169.400
  • Perfiles de microARN como predictores de cáncer de próstata agresivo para mejorar la toma de decisiones terapéuticas.

    Entity where project took place: FUNDACIO INSTITUT DE RECERCA DE L’HOSPITAL UNIV. VALL D’HEBRON
    Name principal investigator (PI, Co-PI….): Juan Morote Robles
    Funding entity or bodies: Fondo de Investigación Sanitaria (PI13/00173) Type of entity: publico. City funding entity: Madrid, Community of Madrid, Spain
    Start-End date: 2014-2016 Duration: 3 years
    Total amount: 57.475,00 €
  • Exosomas de la orina como fuente de biomarcadores para el diagnóstico y pronóstico del cáncer de próstata.

    Entity where project took place: FUNDACIO INSTITUT DE RECERCA DE L’HOSPITAL UNIV. VALL D’HEBRON
    Name principal investigator (PI, Co-PI….): Mireia Olivan
    Funding entity or bodies: Asociación Española Contra el Cáncer
    Start-End date: 2014-2015 Duration: 2 years
    Total amount: 18.000€

View all the research projects